157 related articles for article (PubMed ID: 8486957)
1. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.
Ceesay SJ; Allen SJ; Menon A; Todd JE; Cham K; Carlone GM; Turner SH; Gheesling LL; DeWitt W; Plikaytis BD
J Infect Dis; 1993 May; 167(5):1212-6. PubMed ID: 8486957
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
Rennels MB; Edwards KM; Keyserling HL; Reisinger K; Blatter MM; Quataert SA; Madore DV; Chang I; Malinoski FJ; Hackell JG; Paradiso PR
Pediatr Infect Dis J; 2001 Feb; 20(2):153-9. PubMed ID: 11224833
[TBL] [Abstract][Full Text] [Related]
3. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.
Leach A; Twumasi PA; Kumah S; Banya WS; Jaffar S; Forrest BD; Granoff DM; LiButti DE; Carlone GM; Pais LB; Broome CV; Greenwood BM
J Infect Dis; 1997 Jan; 175(1):200-4. PubMed ID: 8985221
[TBL] [Abstract][Full Text] [Related]
4. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
[TBL] [Abstract][Full Text] [Related]
5. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.
Käyhty H; Karanko V; Peltola H; Sarna S; Mäkelä PH
J Infect Dis; 1980 Dec; 142(6):861-8. PubMed ID: 6780634
[TBL] [Abstract][Full Text] [Related]
6. Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy.
O'Dempsey TJ; McArdle T; Ceesay SJ; Secka O; Demba E; Banya WA; Francis N; Greenwood BM
Arch Dis Child Fetal Neonatal Ed; 1996 Jan; 74(1):F43-6. PubMed ID: 8653435
[TBL] [Abstract][Full Text] [Related]
7. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants.
Poellabauer EM; Pavlova BG; Fritsch S; Singer J; Neubauer C; Doralt J; Valenta-Singer B; Ehrlich HJ
Vaccine; 2013 Aug; 31(35):3611-6. PubMed ID: 23672977
[TBL] [Abstract][Full Text] [Related]
8. Challenges for development of meningococcal vaccines in infants and children.
Deasy A; Read RC
Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
10. Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children.
Badahdah AM; Khatami A; Tashani M; Rashid H; Booy R
Pediatr Infect Dis J; 2018 Mar; 37(3):e66-e71. PubMed ID: 29227467
[TBL] [Abstract][Full Text] [Related]
11. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
12. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants.
Twumasi PA; Kumah S; Leach A; O'Dempsey TJ; Ceesay SJ; Todd J; Broome CV; Carlone GM; Pais LB; Holder PK
J Infect Dis; 1995 Mar; 171(3):632-8. PubMed ID: 7876610
[TBL] [Abstract][Full Text] [Related]
13. Measurement of growth-inhibiting (bactericidal) antibodies in patients with meningococcal meningitis and in subjects immunized with meningococcal polysaccharide vaccine by a [3H]thymidine assay.
Hassan-King M; Greenwood BM; Whittle HC
J Clin Microbiol; 1985 Jul; 22(1):136-8. PubMed ID: 3926814
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
Milagres LG; Gorla MC; Rebelo MC; Barroso DE
FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
[TBL] [Abstract][Full Text] [Related]
15. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
Noronha CP; Struchiner CJ; Halloran ME
Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
[TBL] [Abstract][Full Text] [Related]
17. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
20. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
